References
- Salas-Wright CP, Vaughn MG, Cummings-Vaughn LA, et al. Trends and correlates of marijuana use among late middle-aged and older adults in the United States, 2002–2014. Drug Alcohol Depend. 2017;171:97–106.
- Choi NG, DiNitto DM, Choi BY. Prescription pain reliever use and misuse among cannabis users aged 50+ years. Clin Gerontol. 2020.
- Choi NG, DiNitto DM, Marti CN. Nonmedical versus medical marijuana use among three age groups of adults: associations with mental and physical health status. Am J Addict. 2017;26:697–706.
- National Institute on Drug Abuse. 2020 April. Marijuana. Available from: https://www.drugabuse.gov/sites/default/files/marijuana-research-report.pdf
- National Institute on Drug Abuse. 2018 February. Drug facts: synthetic cannabinoids (K2/Spice). Available from: https://www.drugabuse.gov/sites/default/files/drugfacts-synthcannabinoids.pdf
- Alves VL, Gonçalves JL, Aguiar J, et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. a review. Crit Rev Toxicol. 2020.
- Cohen K, Weinstein A. The effects of cannabinoids on executive functions: evidence from cannabis and synthetic cannabinoids – a systematic review. Brain Sci. 2018;8:40.
- Cooper ZD. Adverse Effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep. 2016;18:52.
- Karila L, Benyamina A, Blecha L, et al. The synthetic cannabinoids phenomenon. Curr Pharm Des. 2016;22:6420–6425.
- Manseau MW, Rajparia A, Joseph A, et al. Clinical characteristics of synthetic cannabinoid use in a large urban psychiatric emergency setting. Subst Use Misuse. 2017;52:822–‐825.
- Riederer AM, Campleman SL, Carlson RG, et al.; Toxicology Investigators Consortium (ToxIC). Acute poisonings from synthetic cannabinoids – 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65:692–695.
- Roehler DR, Hoots BE, Vivolo-Kantor AM. Regional trends in suspected synthetic cannabinoid exposure from January 2016 to September 2019 in the United States. Drug Alcohol Depend. 2020;207:107810.
- U.S. Food and Drug Administration. FDA regulation of cannabis and cannabis-derived products including cannabidiol (CBD). 2020 Mar 11. Available from: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd#approved
- Wang GS, Hall K, Vigil D, et al. Marijuana and acute health care contacts in Colorado. Prev Med. 2017;104:24–30.
- Monte AA, Shelton SK, Mills E, et al. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med. 2019;170:531–537.
- Choi NG, DiNitto DM, Arndt S. Potential harms of marijuana use among older adults. Public Policy Aging Rep. 2019;29:88–94.
- Brown JD, Costales B, van Boemmel-Wegmann S, et al. Characteristics of older adults who were early adopters of medical cannabis in the Florida medical marijuana use registry. JCM. 2020;9:1166.
- Giombi KC, Kosa KM, Rains C, et al. Consumers’ perceptions of edible marijuana products for recreational use: likes, dislikes, and reasons for use. Subst Use Misuse. 2018;53:541–547.
- Choi NG, DiNitto DM, Marti CN. Older-adult marijuana users and ex-users: comparisons of sociodemographic characteristics and mental and substance use disorders. Drug Alcohol Depend. 2016;165:94–102.
- Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol. 2019;57:1220–1413.
- Allison P. When can you safely ignore multicollinearity? Available from: https://statisticalhorizons.com/multicollinearity
- Lachenmeier DW, Habel S, Fischer B, et al. Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? F1000Res. 2019;8:1394.
- Golombek P, Müller M, Barthlott I, et al. Conversion of cannabidiol (CBD) into psychotropic cannabinoids including tetrahydrocannabinol (THC): a controversy in the scientific literature. Toxics. 2020;8:41.
- Boggs DL, Nguyen JD, Morgenson D, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol. Neuropsychopharmacology. 2018;43:142–154.
- Gourdet C, Giombi KC, Kosa K, et al. How four U.S. states are regulating recreational marijuana edibles. Int J Drug Policy. 2017;43:83–90.
- Law R, Schier J, Martin C, et al.; Centers for Disease Control (CDC). Centers for Disease Control (CDC). Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use – United States, January–May 2015. MMWR Morb Mortal Wkly Rep. 2015;64:618–619.
- White CM. The pharmacologic and clinical effects of illicit synthetic cannabinoids. J Clin Pharmacol. 2017;57:297–304.
- Hughes A, Hendrickson RG. An epidemiologic and clinical description of e-cigarette toxicity. Clin Toxicol. 2019;57:287–293.
- Zaurova M, Hoffman RS, Vlahov D, et al. Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. J Med Toxicol. 2016;12:335–340.